A photo of Brian Weiss.

Brian D. Weiss, MD

  • Medical Director, Solid Tumor Program
  • Director, Neuroblastoma Program
  • Associate Director for Safety and Compliance
  • Professor, UC Department of Pediatrics



I specialize in caring for children with neuroblastoma and neurofibromatosis type 1 (NF1) related plexiform neurofibromas. I research novel therapies and targeted radiotherapy to treat neuroblastoma, particularly high-risk neuroblastoma. I am also investigating the development of targeted therapies for NF1 related plexiform neurofibromas.

My interest in clinical practice and research stems from my love and desire to care for children and help their families. I have a strong determination to make a difference in the lives of every individual. The ultimate research goal is to find a cure for these disorders.

In addition, in my role as associate director for Safety and Compliance, I have spearheaded efforts to reduce chemotherapy errors. In this effort, I have led a multi-disciplinary team that has significantly and consistently improved our safety around chemotherapy.

I am certified in Pediatrics (1996, 2002) and Pediatric Hematology-Oncology (2000, 2007, 2019) by the National Medical Board. My work is published in many well-respected journals, including The New England Journal of Medicine, Bone Marrow Transplantation, BMJ Quality and Safety, Pediatric Blood and Cancer, Clinical Cancer Research, American Journal of Medical Genetics and the Journal of Pediatric Gastroenterology and Nutrition.

MD: Northwestern University Medical School, Chicago, IL, 1993.

Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997.

Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000.

Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007.


Targeted agents for neurofibromatosis type 1-related plexiform neurofibromas and other solid tumors; new therapies for high-risk neuroblastoma, including 131I-MIBG treatment and other new approaches to targeting and killing neuroblastoma cells.

Services and Specialties

Cancer and Blood Diseases, Neuroblastoma, Neurofibromatosis, Rasopathy

Research Areas

Oncology, Cancer and Blood Diseases

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information



High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Jodele, S; Dandoy, CE; Myers, K; Wallace, G; Lane, A; Teusink-Cross, A; Weiss, B; Davies, SM. Bone Marrow Transplantation. 2018; 53:1311-1318.

Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Heczey, A; Xu, X; Courtney, AN; Tian, G; Barragan, GA; Guo, L; Amador, CM; Ghatwai, N; Rathi, P; Wood, MS; et al. Nature Medicine. 2023; 29:1379-1388.

Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. Lerman, BJ; Li, Y; Carlowicz, C; Granger, M; Cash, T; Sadanand, A; Somers, K; Ranavaya, A; Weiss, BD; Choe, M; et al. Journal of Clinical Oncology. 2023; 41:508-516.

Management of neurofibromatosis type 1-associated plexiform neurofibromas. Fisher, MJ; Blakeley, JO; Weiss, BD; Dombi, E; Ahlawat, S; Akshintala, S; Belzberg, AJ; Bornhorst, M; Bredella, MA; Cai, W; et al. Neuro-Oncology. 2022; 24:1827-1844.

MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. De Blank, PM K; Gross, AM; Akshintala, S; Blakeley, JO; Bollag, G; Cannon, A; Dombi, E; Fangusaro, J; Gelb, BD; Hargrave, D; et al. Neuro-Oncology. 2022; 24:1845-1856.

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. DuBois, SG; Granger, MM; Groshen, S; Tsao-Wei, D; Ji, L; Shamirian, A; Czarnecki, S; Goodarzian, F; Berkovich, R; Shimada, H; et al. Journal of Clinical Oncology. 2021; 39:3506-3514.

A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. Weiss, BD; Yanik, G; Naranjo, A; Zhang, FF; Fitzgerald, W; Shulkin, BL; Parisi, MT; Russell, H; Grupp, S; Pater, L; et al. Pediatric Blood and Cancer. 2021; 68:e29117.

Prognostic significance of pretreatment 18F-FDG positron emission tomography/computed tomography in pediatric neuroblastoma. Sung, AJ; Weiss, BD; Sharp, SE; Zhang, B; Trout, AT. Pediatric Radiology: roentgenology, nuclear medicine, ultrasonics, CT, MRI. 2021; 51:1400-1405.

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Granger, MM; Naranjo, A; Bagatell, R; DuBois, SG; McCune, JS; Tenney, SC; Weiss, BD; Mosse, YP; Asgharzadeh, S; Grupp, SA; et al. Transplantation and cellular therapy. 2021; 27:490.e1-490.e8.

Metastatic neuroblastoma masquerading as infantile hemangioma in a 4-month-old child. Karkoska, K; Ricci, K; VandenHeuvel, K; Trout, AT; Smith, EA; Kotagal, M; Weiss, B. Pediatric Blood and Cancer. 2021; 68:e28920.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Overall Patient Rating